These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 21596119)

  • 1. The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate.
    Do TT; Van Speybroeck M; Mols R; Annaert P; Martens J; Van Humbeeck J; Vermant J; Augustijns P; Van den Mooter G
    Int J Pharm; 2011 Jul; 414(1-2):118-24. PubMed ID: 21596119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments.
    O'Shea JP; Faisal W; Ruane-O'Hora T; Devine KJ; Kostewicz ES; O'Driscoll CM; Griffin BT
    Eur J Pharm Biopharm; 2015 Oct; 96():207-16. PubMed ID: 26215636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles.
    Juenemann D; Jantratid E; Wagner C; Reppas C; Vertzoni M; Dressman JB
    Eur J Pharm Biopharm; 2011 Feb; 77(2):257-64. PubMed ID: 21074611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine.
    Devraj R; Williams HD; Warren DB; Mohsin K; Porter CJ; Pouton CW
    Eur J Pharm Sci; 2013 Jul; 49(4):748-60. PubMed ID: 23684915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solid self-nanoemulsifying drug delivery system (S-SNEDDS) of darunavir for improved dissolution and oral bioavailability: In vitro and in vivo evaluation.
    Inugala S; Eedara BB; Sunkavalli S; Dhurke R; Kandadi P; Jukanti R; Bandari S
    Eur J Pharm Sci; 2015 Jul; 74():1-10. PubMed ID: 25845633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-microemulsifying smaller molecular volume oil (Capmul MCM) using non-ionic surfactants: a delivery system for poorly water-soluble drug.
    Bandivadeka MM; Pancholi SS; Kaul-Ghanekar R; Choudhari A; Koppikar S
    Drug Dev Ind Pharm; 2012 Jul; 38(7):883-92. PubMed ID: 22087760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining in vitro and in silico methods for better prediction of surfactant effects on the absorption of poorly water soluble drugs-a fenofibrate case example.
    Berthelsen R; Sjögren E; Jacobsen J; Kristensen J; Holm R; Abrahamsson B; Müllertz A
    Int J Pharm; 2014 Oct; 473(1-2):356-65. PubMed ID: 24997410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal behavior of nano- and microsized fenofibrate: In vivo evaluation in man and in vitro simulation by assessment of the permeation potential.
    Hens B; Brouwers J; Corsetti M; Augustijns P
    Eur J Pharm Sci; 2015 Sep; 77():40-7. PubMed ID: 26004010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of a discriminant and biorelevant in vitro dissolution test for the development of fenofibrate self-emulsifying lipid-based formulations.
    Pestieau A; Krier F; Brouwers A; Streel B; Evrard B
    Eur J Pharm Sci; 2016 Sep; 92():212-9. PubMed ID: 27169683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of lipid-based formulations for oral administration of poorly water-soluble drug fenofibrate: effects of digestion.
    Mohsin K
    AAPS PharmSciTech; 2012 Jun; 13(2):637-46. PubMed ID: 22547370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of oral bioavailability of fenofibrate by solid self-microemulsifying drug delivery systems.
    Kim GG; Poudel BK; Marasini N; Lee DW; Hiep TT; Yang KY; Kim JO; Yong CS; Choi HG
    Drug Dev Ind Pharm; 2013 Sep; 39(9):1431-8. PubMed ID: 23046292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate.
    Jia Z; Lin P; Xiang Y; Wang X; Wang J; Zhang X; Zhang Q
    Eur J Pharm Biopharm; 2011 Sep; 79(1):126-34. PubMed ID: 21658449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of different polysorbates on development of self-microemulsifying drug delivery systems using medium chain lipids.
    Shah A; Thool P; Sorathiya K; Prajapati H; Dalrymple D; Serajuddin ATM
    Drug Dev Ind Pharm; 2018 Feb; 44(2):215-223. PubMed ID: 29057677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system.
    Buch P; Langguth P; Kataoka M; Yamashita S
    J Pharm Sci; 2009 Jun; 98(6):2001-9. PubMed ID: 18855916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.
    Suys EJA; Chalmers DK; Pouton CW; Porter CJH
    Mol Pharm; 2018 Jun; 15(6):2355-2371. PubMed ID: 29659287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterisation of fenofibrate dissolution delivered by a self-microemulsifying drug-delivery system.
    Wei JD; Ho HO; Chen CH; Ke WT; Chen ET; Sheu MT
    J Pharm Pharmacol; 2010 Dec; 62(12):1685-96. PubMed ID: 21054394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simplified method to screen for in-vivo performance of oral lipid formulations.
    Kilic M; Dressman J
    J Pharm Pharmacol; 2014 May; 66(5):615-23. PubMed ID: 24313318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate.
    Griffin BT; Kuentz M; Vertzoni M; Kostewicz ES; Fei Y; Faisal W; Stillhart C; O'Driscoll CM; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2014 Apr; 86(3):427-37. PubMed ID: 24184675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of lipid-based formulations for oral administration of poorly water-soluble drugs: precipitation of drug after dispersion of formulations in aqueous solution.
    Mohsin K; Long MA; Pouton CW
    J Pharm Sci; 2009 Oct; 98(10):3582-95. PubMed ID: 19130605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.